Prasinezumab is a humanized monoclonal antibody designed to bind aggregated α-synuclein and inhibit the intercellular spread of pathogenic α-synuclein, thus potentially protecting neurons and slowing Parkinson’s disease (PD) progression1–3. Here, SNCA is linked to Parkinson disease.